Ardana PLC
27 March 2008
Ardana plc
UPDATE ON THE PROPOSED SALE OR MERGER OF THE COMPANY
Edinburgh, UK, 27 March 2008 - Ardana plc ('Ardana' or the 'Company') (LSE:ARA)
the pharmaceutical company specialising in improving human reproductive health,
today provides an update to shareholders on developments in relation to the
proposed sale or merger of the Company (the 'Process'), as announced on 19
February 2008.
Since the announcement, the Company has held discussions with a significant
number of interested parties. Even at this early stage, the Company can confirm
that it has received a number of approaches which may or may not lead to an
offer for the Company. It is the Board's intention to ensure that all interested
parties are brought rapidly to the same point in the Process, such that the
Board will be in a position to compare all potential offers equitably.
In addition, the Process has generated significant interest in potential
licensing opportunities for one or more of the Company's products. The Board is
progressing these licensing discussions in parallel with the Process, to ensure
that the Company is in a position to maximise shareholder value at the
appropriate time. However, the Board will only pursue a licensing transaction if
it does not negatively affect the value of the Company in the view of potential
acquirers.
Given the level of interest in the Company and its products generated by the
Process to date, the Board sees no reason for the significant fall in share
price since the announcement on 19 February 2008.
A further update will be provided to shareholders in due course.
For more information contact:
Ardana plc Financial Dynamics
Dr. Huw Jones - Chief Executive Officer Julia Phillips
Graham Lee - Chief Financial Officer Emma Thompson
Tel: + 44 (0) 131 226 8550 Tel: +44 (0)20 7831 3113
Piper Jaffray Ltd.
Neil Mackison
James Steel
Tel: +44 (0)20 3142 8700
For further information please see www.ardana.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.